Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

Clinical Journal of the American Society of Nephrology : CJASN
Marie E EdwardsVicente E Torres

Abstract

In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.6±2.8; range, 1.1-11.2) were analyzed for efficacy using three approaches: (1) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; (2) Stability of eGFR slopes with duration of follow-up; and (3) compar...Continue Reading

References

May 1, 1983·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C G IglesiasL T Kurland
Oct 30, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·V E Torres, M L Watson
Jul 28, 2001·Kidney International·P AnastasioN G De Santo
Feb 14, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Pascale BardouxLise Bankir
Mar 13, 2003·Kidney International·Robert W SchrierAnn M Johnson
Mar 3, 2004·Nature Medicine·Vicente E TorresVincent H Gattone
Aug 26, 2004·Kidney International·Franck A BelibiJared J Grantham
Feb 25, 2005·Journal of the American Society of Nephrology : JASN·Xiaofang WangVicente E Torres
May 19, 2006·The New England Journal of Medicine·Jared J GranthamUNKNOWN CRISP Investigators
Jun 30, 2006·Journal of the American Society of Nephrology : JASN·Shizuko NagaoDarren P Wallace
Aug 16, 2006·Annals of Internal Medicine·Andrew S LeveyUNKNOWN Chronic Kidney Disease Epidemiology Collaboration
Nov 23, 2007·Journal of the American Society of Nephrology : JASN·Xiaofang WangVicente E Torres
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
May 16, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Vicente E TorresJared J Grantham
Jul 31, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Bjarne OrskovSvend Strandgaard
Apr 5, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Christine PatchMartin C Gulliford
Sep 10, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Eiji HigashiharaUNKNOWN TEMPOFormula and 156-05-002 Study Investigators
Feb 22, 2012·Clinical Journal of the American Society of Nephrology : CJASN·Arlene B ChapmanJared J Grantham
Nov 6, 2012·The New England Journal of Medicine·Vicente E TorresUNKNOWN TEMPO 3:4 Trial Investigators
Feb 27, 2013·Nature Reviews. Nephrology·Lise BankirEberhard Ritz
Feb 27, 2014·The Journal of Pharmacology and Experimental Therapeutics·Miki AiharaYoshitaka Yamamura
Jun 7, 2014·Journal of the American Society of Nephrology : JASN·María V IrazabalUNKNOWN CRISP Investigators
Jul 6, 2014·Journal of the American Society of Nephrology : JASN·Katharina HoppVicente E Torres
Nov 18, 2014·The New England Journal of Medicine·Vicente E TorresUNKNOWN HALT-PKD Trial Investigators
Dec 17, 2014·American Journal of Physiology. Renal Physiology·Katharina HoppVicente E Torres
Jan 21, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Wendy E BoertienRon T Gansevoort
Jun 20, 2015·Lancet·Albert C M OngUNKNOWN ERA-EDTA Working Group for Inherited Kidney Diseases
Jul 21, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Paul B WatkinsChristopher A Zimmer
Dec 21, 2016·Kidney International·Vicente E TorresMichael F Flessner
Apr 27, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Vicente E TorresUNKNOWN TEMPO 4:4 Trial Investigators
Nov 7, 2017·The New England Journal of Medicine·Julie R Ingelfinger
Nov 7, 2017·The New England Journal of Medicine·Vicente E TorresUNKNOWN REPRISE Trial Investigators
Nov 10, 2017·Journal of the American Society of Nephrology : JASN·Kristen L NowakMichel Chonchol

❮ Previous
Next ❯

Citations

Jul 28, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Fouad T Chebib, Vicente E Torres
Sep 20, 2018·Journal of the American Society of Nephrology : JASN·Fouad T ChebibVicente E Torres
Oct 13, 2018·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Vicente E Torres
Mar 12, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Eric H J VerschurenJoost G J Hoenderop
Mar 13, 2020·Stem Cells Translational Medicine·Annegien T KenterJoost H Gribnau
Sep 7, 2019·Nature Reviews. Nephrology·Luis Fernando Menezes, Gregory G Germino
Dec 8, 2020·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Harold M Aukema
Feb 5, 2021·Proceedings of the National Academy of Sciences of the United States of America·Sharon BaroneManoocher Soleimani
Apr 27, 2020·Cellular Signalling·Caroline R SussmanVicente E Torres
Mar 12, 2021·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Fouad T Chebib, Vicente E Torres
Mar 22, 2021·Pharmacology & Therapeutics·Dagmar Wachten, David U Mick
May 6, 2021·Therapeutic Advances in Chronic Disease·Julia MoosmannChristoph Kopp
Jul 9, 2021·Therapeutics and Clinical Risk Management·Ioannis Bellos
Jul 3, 2021·International Journal of Molecular Sciences·Adrian CordidoMiguel A Garcia-Gonzalez
Jul 16, 2021·Current Opinion in Nephrology and Hypertension·Esther Meijer, Ron T Gansevoort
Apr 2, 2020·Case Reports in Nephrology and Dialysis·Shinya NakataniMasaaki Inaba

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Vicente E TorresTEMPO 4:4 Trial Investigators
Clinical Journal of the American Society of Nephrology : CJASN
Vicente E TorresTEMPO 3:4 Trial Investigators
The New England Journal of Medicine
Vicente E TorresREPRISE Trial Investigators
© 2022 Meta ULC. All rights reserved